Statements (39)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Dragon
|
| gptkbp:antidote |
gptkb:antitoxin
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
M03AX01
|
| gptkbp:brand |
gptkb:Botox
gptkb:Dysport gptkb:Jeuveau gptkb:Xeomin |
| gptkbp:CASNumber |
93384-43-1
|
| gptkbp:category |
gptkb:protein
gptkb:bacterial_toxin therapeutic protein neuroparalytic agent |
| gptkbp:class |
biological weapon (potential)
|
| gptkbp:discoveredBy |
gptkb:Emile_van_Ermengem
|
| gptkbp:discoveredIn |
1895
|
| gptkbp:mechanismOfAction |
inhibits acetylcholine release
|
| gptkbp:molecularWeight |
~150 kDa
|
| gptkbp:producedBy |
gptkb:Clostridium_botulinum
|
| gptkbp:routeOfAdministration |
intramuscular injection
|
| gptkbp:sideEffect |
muscle weakness
allergic reaction ptosis dysphagia |
| gptkbp:structure |
composed of heavy and light chains
|
| gptkbp:toxicity |
extremely potent
|
| gptkbp:UNII |
J3M7L9675F
|
| gptkbp:usedFor |
treatment of blepharospasm
treatment of cervical dystonia treatment of chronic migraine treatment of overactive bladder treatment of sialorrhea treatment of strabismus treatment of hyperhidrosis treatment of muscle spasticity cosmetic reduction of wrinkles |
| gptkbp:bfsParent |
gptkb:SNAP-25
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
botulinum neurotoxin A
|